Availability of anti-tuberculosis drugs in Europe: Table 1–

Availability of anti-tuberculosis drugs in Europe.

Acknowledgements: The members of the SMIRA Group were: C. Piersimoni (Ospedali Riuniti, Ancona, Italy); P. Lorenzetti (Ospedale di Aosta, Aosta, Italy); D. Costa (Policlinico di Bari, Bari, Italy); A. Grimaldi (Ospedale Fallacara, Triggiano, Bari, Italy); M. Arosio and A. Goglio (Ospedali Riuniti, Bergamo, Italy); C. Mazza and L. Squintani (Ospedale Maggiore, Bologna, Italy); C. Larcher and E. ...

Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey.

Data on availability and cost of anti-tuberculosis (TB) drugs in relation to affordability at national level are scarce. We performed a cross-sectional study on availability and cost of anti-TB drugs at major TB-reference centres in 37 European countries. Costs of standardised treatment regimens used for pan-sensitive TB, multidrug-resistant (MDR) TB, pre-extensively drug-resistant (XDR) TB, an...

STUDY ON THE HEPATOTOXICITY OF ANTI-TUBERCULOSIS DRUGS IN 190 PATIE NTS WITH PULMONARY AND E XTRAPULMONARY TUBERCULOSIS

Tuberculosis is one of the oldest diseases that affects humans. The cause of this disease is Mycobacterium tuberculosis. This disease affects approximately 8.8 million people worldwide and led to over 3 million deaths in 1995. 95% of those affected and 98% of deaths occurred in developing countries. Hepatic reactions constitute a major proportion of drug reactions to antituberculosis drugs ...

Clinical development of anti-tuberculosis drugs.

In the clinical development of new anti-tuberculosis drugs, the most important step is efficient Phase II studies to show whether the drug is likely to be able to shorten treatment and with what other drugs it has the greatest sterilizing activity. The use of non-linear mixed effects modelling applied to serial sputum cfu counts appears to be the most effective technique, but we know little abo...

drug-resistant tuberculosis and group 5 anti-tuberculosis drugs